latest news releases from the newsroom
BioXell's Phase IIa trial in BPH is fully enrolled
MILAN, Italy, Nov. 28, 2003 (PRIMEZONE) -- Milan, Italy, November 28, 2003 - BioXell SpA, today announced that it has completed patient enrolment in the Phase IIa trial of its novel lead compound, BXL-628, in Benign Prostatic Hyperplasia (BPH).The double-blind, randomised, placebo-controlled trial is being coordinated by the Division of Urology of the San Raffaele Hospital in Milan and involves 12 centres across Italy. The primary end-point of this 3 month study is prostate size reduction as measured by MRI scans, with secondary end-points being reduced symptom severity and urinary flow rate. Results are expected in the first half of 2004.
Skanska sells three properties in Denmark for SEK 313 M
STOCKHOLM, Sweden, Nov. 28, 2003 (PRIMEZONE) -- Skanska is divesting three properties in Copenhagen, at Holbergsgade 2- 3, Tordenskjoldsgade 20-24 and Niels Juels gade 5. The total sale price is SEK 313 M and represents a capital loss of SEK 17 M. The sale is being reported in the fourth quarter 2003, with transfer expected in December 2003. The buyer is the Danish real estate company Atlas Ejendomme.
French-Danish couple won the Spirit & Strength international quilt competition
HUSKVARNA, Sweden, Nov. 28, 2003 (PRIMEZONE) -- Inge Mardal and Steen Hougs won the Spirit & Strength international quilt competition against stiff competition comprising textile artists from 15 countries. The couple were recently awarded their first prize of a sewing machine worth around 50,000 Swedish kronor, Swedish glass sculpture by artist Bertil Vallien and 2,500 US dollars at a ceremony at the Houston International Quilt Festival, the world's largest quilt fair.
Diamyd, Inc. wins dispute with Diarect AG
STOCKHOLM, Sweden, Nov. 27, 2003 (PRIMEZONE) -- Diamyd Medical AB (listed on the Swedish Stock Exchange, O-list) develops a treatment for insulin dependent diabetes, Diamyd(TM). There has been an ongoing dispute since one year between a subsidiary, i.e. Diamyd, Inc., Akron, Ohio, USA and Diarect AG, Freiburg, Germany, regarding the termination of a distribution agreement concerning Diamyd's right to market products from Diarect on the North American market.
Proposal for the Composition of Boliden's Board of Directors
STOCKHOLM, Sweden, Nov. 27, 2003 (PRIMEZONE) -- In view of the transaction between Boliden and Outokumpu, Boliden shareholders representing approximately 30 percent of the total number of shares and votes in the company have informed Boliden that at the extraordinary shareholders' meeting to be held on December 18, 2003 they will jointly propose that:
Gambro Won Tax Ruling
STOCKHOLM, Sweden, Nov. 27, 2003 (PRIMEZONE) -- Gambro AB (Stockholmsborsen:GAMBaST) (Stockholmsborsen:GAMBbST), a leading international medical technology and healthcare company, today announced that the Lower Tax Court (Lansratten) has confirmed the advance ruling by the Supreme Administrative Court regarding the fiscal acquisition value of previously divested ABB shares. The ruling means that Gambro has been given access to approximately MSEK 2,182 of carry-forward losses with a tax effect of MSEK 611. Together with an earlier ruling this corresponds to a tax saving of MSEK 894, which will be recognized as income in the fourth quarter 2003. There will not be any cash flow effect in 2003, but tax payments will be reduced in the coming years. The ruling might be appealed.
Sapa Invests 195 MSEK in New Technology
STOCKHOLM, Sweden, Nov. 27, 2003 (PRIMEZONE) -- Sapa rationalises by investing 195 MSEK in a new vertical anodising plant at Sapa Profiler in Vetlanda, Sweden. The investment in new and modern surface treatment technology will lead to increased efficiency and improved working conditions through automated production. The new plant is estimated to be in production during the first half of 2006. At the same time the production at existing plants will be moved to the new one and the old ones will be closed down.